Evidence map›Paper›PMID 40462712›Full record

ArticleJournal of the Royal Society, Interface2025

Scientific hypothesis generation by large language models: laboratory validation in breast cancer treatment.

Abbi Abdel-Rehim, Hector Zenil, Oghenejokpeme Orhobor, Marie Fisher, Ross J Collins, Elizabeth Bourne, Gareth W Fearnley, Emma Tate, Holly X Smith, Larisa N Soldatova and 1 more

Abstract read
In one paragraph

Article in Journal of the Royal Society, Interface, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Capacity of Understanding the Future Approaches in Cancer Treatment by Multiple Models of Artificial Intelligence.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026
    Article
  5. Review
  6. Review
  7. AI for clinical trials in oncology.ESMO real world data and digital oncology · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abbi Abdel-RehimDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Hector ZenilDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-0634-4384
Oghenejokpeme OrhoborDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Marie FisherArctoris Ltd, Oxford, UK.
Ross J CollinsArctoris Ltd, Oxford, UK.
Elizabeth BourneArctoris Ltd, Oxford, UK.
Gareth W FearnleyArctoris Ltd, Oxford, UK.
Emma TateArctoris Ltd, Oxford, UK.
Holly X SmithArctoris Ltd, Oxford, UK.
Larisa N SoldatovaComputer Science, Goldsmiths University of London, London, UK.
Ross KingDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.ORCID 0000-0001-7208-4387

Funding

the Wallenberg AI, Autonomous Systems and Software ProgramUK Engineering and Physical Sciences Research Council (EPSRC)
6 · The paper itself

Abstract

Large language models (LLMs) have transformed artificial intelligence (AI) and achieved breakthrough performance on a wide range of tasks. In science, the most interesting application of LLMs is for hypothesis formation. A feature of LLMs, which results from their probabilistic structure, is that the output text is not necessarily a valid inference from the training text. These are termed 'hallucinations', and are harmful in many applications. In science, some hallucinations may be useful: novel hypotheses whose validity may be tested by laboratory experiments. Here, we experimentally test the application of LLMs as a source of scientific hypotheses using the domain of breast cancer treatment. We applied the LLM GPT4 to hypothesize novel synergistic pairs of US Food and Drug Administration (FDA)-approved non-cancer drugs that target the MCF7 breast cancer cell line relative to the non-tumorigenic breast cell line MCF10A. In the first round of laboratory experiments, GPT4 succeeded in discovering three drug combinations (out of 12 tested) with synergy scores above the positive controls. GPT4 then generated new combinations based on its initial results, this generated three more combinations with positive synergy scores (out of four tested). We conclude that LLMs are a valuable source of scientific hypotheses.

Indexed as

Artificial IntelligenceBreast NeoplasmsModels, BiologicalFemaleHumansLarge Language ModelsMCF-7 Cellsartificial intelligence for sciencecancer researchdrug discoverymachine learningpersonalized medicine

Identifiers

PMID40462712
PMCPMC12134935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.